1-hydroxymethylmidazolam has been researched along with fexofenadine in 1 studies
Studies (1-hydroxymethylmidazolam) | Trials (1-hydroxymethylmidazolam) | Recent Studies (post-2010) (1-hydroxymethylmidazolam) | Studies (fexofenadine) | Trials (fexofenadine) | Recent Studies (post-2010) (fexofenadine) |
---|---|---|---|---|---|
163 | 46 | 49 | 700 | 226 | 256 |
Protein | Taxonomy | 1-hydroxymethylmidazolam (IC50) | fexofenadine (IC50) |
---|---|---|---|
Histamine H1 receptor | Homo sapiens (human) | 0.0623 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H | 1 |
1 other study(ies) available for 1-hydroxymethylmidazolam and fexofenadine
Article | Year |
---|---|
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Urea Nitrogen; Cytochrome P-450 CYP3A; Enterocytes; Female; Hepatocytes; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Organic Anion Transporters; Prospective Studies; Rats; Rats, Sprague-Dawley; Terfenadine | 2009 |